CC-42344 - Influenza A PB2 Inhibitor

Program Discovery Preclinical Phase 1 Phase 2 Phase 3
Influenza A Oral PB2 Inhibitor CC-42344
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

CC-42344, our novel, broad-spectrum, orally administered antiviral investigational candidate for a potential treatment of pandemic and seasonal influenza A infection.  It binds to a highly conserved PB2 site of influenza A polymerase complex and exhibits a novel mechanism of action which inhibits replication. We began enrolling subjects in a Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza A in the first quarter of 2022. The study is being conducted in Australia and is designed to assess the safety, tolerability and pharmacokinetics of CC-42344 with results expected in 2022.

In vitro testing showed CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu® and Xofluza™, while also demonstrating favorable pharmacokinetic and safety profiles. CC-42344 inhibits the first step in influenza A’s viral replication by binding to a highly conserved PB2 site of the influenza polymerase complex that is essential to replication. We discovered CC-42344 using our proprietary structure-based drug discovery platform technology.